The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice
Open accessThe DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated viruses (AAVs) have been used widely for in vivo gene therapy. However, adaptive immune responses to AAV have posed a significant hurdle in clinical application of AAV vectors. Recent advances have suggested a crucial role for innate immunity in shaping adaptive immune responses. How AAV activates innate immunity, and thereby promotes AAV-targeted adaptive immune responses, remains unknown. Here we show that AAV activates mouse plasmacytoid DCs (pDCs) via TLR9 to produce type I IFNs. In vivo, the TLR9-MyD88 pathway was crucial to the activation of CD8+ T cell responses to both the transgene product and the AAV capsid, leading to loss of transgene expression and the generation of transgene product-specific and AAV-neutralizing antibodies. We further demonstrate that TLR9-dependent activation of adaptive immunity targeting AAV was mediated by type I IFNs and that human pDCs could be activated in vitro to induce type I IFN production via TLR9. These results reveal an essential role for the TLR9-MyD88-type I IFN pathway in induction of adaptive immune responses to AAV and suggest that strategies that interfere with this pathway may improve the outcome of AAV-mediated gene therapy in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We confirmed with Myd88−/− mice that development of CD8+ T cell responses against rh32.33 capsid depended on MyD88(15, 17) (Fig. 2A, middle panel).”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We confirmed with Tlr9−/− and Myd88−/− mice that the innate immune response to self-complementary AAV was indeed dependent on the TLR9/MyD88 pathway (Fig. 1D and 1E), as previously shown in the literature (15–17).”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Microglia are the chief resident immune cells of the retina and are capable of inducing pro-inflammatory cytokine expression through TLR9- and TLR2-mediated responses,41 which have been demonstrated to detect AAV genomes and capsids, respectively.42, 43, 44”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unmethylated CpG elements elicit innate immunity and CTL response through TLR9/MyD88-dependent pathway (23).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous animal studies have shown the immune-activating effects of CpG motifs in AAV (23, 150, 151).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [23]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
Toll-like receptor control of the adaptive immune responses
Iwasaki, A., & Medzhitov, R. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,193
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
The Nature of the Principal Type 1 Interferon-Producing Cells in Human Blood
Siegal, F. P., Kadowaki, N., Shodell, M., Fitzgerald-Bocarsly, P. A., Shah, K., Ho, S., Antonenko, S., & Liu, Y.-J. (1999) · Science · doi:10.1126/science.284.5421.1835 · Cited by 2,293
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Innate immune recognition of viral infection
Kawai, T., & Akira, S. (2006) · Nature Immunology · doi:10.1038/ni1303 · Cited by 1,899
Recognition of single-stranded RNA viruses by Toll-like receptor 7
Lund, J. M., Alexopoulou, L., Sato, A., Karow, M., Adams, N. C., Gale, N. W., Iwasaki, A., & Flavell, R. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400937101 · Cited by 1,861
Plasmacytoid dendritic cells in immunity
Colonna, M., Trinchieri, G., & Liu, Y.-J. (2004) · Nature Immunology · doi:10.1038/ni1141 · Cited by 1,678
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Dzionek, A., Fuchs, A., Schmidt, P., Cremer, S., Zysk, M., Miltenyi, S., Buck, D. W., & Schmitz, J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6037 · Cited by 1,298
Cited by
Items 201–300 of 345
Optimizing NTS-Polyplex as a Tool for Gene Transfer to Cultured Dopamine Neurons
Hernández-Baltazar, D., Martínez‐Fong, D., & Trudeau, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051341 · Cited by 18
“concerns with potential immune reactions to viral vectors [10,11]”
BackgroundLu, M., Lee, Z., & Hu, W. (2024) · Biotechnology Progress · doi:10.1002/btpr.3428 · Cited by 18
“45,46 Triple transfection also introduced Ad helper genes to cells.”
BackgroundDuan, D., & Herzog, R. W. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.067 · Cited by 24
Cameron, A. D., Even, K. M., Linardi, R. L., Berglund, A. K., Schnabel, L. V., Engiles, J. B., & Ortved, K. F. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.319 · Cited by 16
“44 Characterization of toll-like receptors in MSCs has confirmed that the TLR9-MyD88 pathway is present 45 ; therefore, it is possible that AAV transduction leads to increased production type I IFNs such as IFN-a and IFN-b in the culture system and it is well known that priming of BM-MSCs with…”
New insights into the role of IFN-α/β and TLR7/8/9 in cancer immunotherapy and systemic autoimmunity
Krieg, A. Μ. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012165 · Cited by 18
AAV Vectored Immunoprophylaxis for Filovirus Infections
Rghei, A. D., van Lieshout, L. P., Santry, L. A., Guilleman, M. M., Thomas, S. P., Susta, L., Karimi, K., Bridle, B. W., & Wootton, S. K. (2020) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed5040169 · Cited by 17
“The ability of AAV vectors to achieve long-term transgene expression has been attributed to their relatively low immunogenicity [166–168]; however, AAV vectors have been shown to activate various Toll like receptors (TLRs) and this can have an influence on the outcome of gene transfer [169,170].”
BackgroundGenome editing for primary immunodeficiencies: A therapeutic perspective on Wiskott-Aldrich syndrome
Naseem, A., Steinberg, Z., & Cavazza, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.966084 · Cited by 17
“Despite their minimal genomes, AAV6 vectors can trigger innate immune responses in HSPCs via innate immune receptors such as Toll-like receptor 9 (TLR9) which senses microbial dsDNA containing unmethylated CpG motifs, and TLR2 (118, 119).”
BackgroundVirus Infection Recognition and Early Innate Responses to Non-Enveloped Viral Vectors
Shayakhmetov, D. M. (2010) · Viruses · doi:10.3390/v2010244 · Cited by 18
“Importantly, they further demonstrated that TLR9-MyD88 pathway was critical for the activation of CD8+ T cell responses to both the transgene product and AAV capsid in vivo, leading to the generation of both transgene product-specific and AAV capsid-specific neutralizing antibodies [105].”
BackgroundAnchim, A., Raddi, N., Zig, L., Perrieau, P., Goffic, R. L., Ryffel, B., & Benihoud, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00124 · Cited by 16
“This cytokine was shown to promote IgG2b and IgG2c production while reducing IgG1 level (36, 37).”
BackgroundAlpha 1 Antitrypsin Gene Therapy Extends the Lifespan of Lupus-Prone Mice
Elshikha, A. S., Yuan, Y., Lu, Y., Chen, M., Abboud, G., Akbar, M. A., Plate, H., Wolney, H., Hoffmann, T., Tagari, E., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.007 · Cited by 20
Tyrosine Mutation in AAV9 Capsid Improves Gene Transfer to the Mouse Lung
Martini, S. V., da Silva, A. L., Pires-Ferreira, D., Rabelo, R., Ornellas, F. M., Gomes, K., Rocco, P. R. M., Petrs‐Silva, H., & Morales, M. M. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000445646 · Cited by 16
Advances in Overcoming Immune Responses following Hemophilia Gene Therapy
H. Miao, C. (2012) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-007 · Cited by 15
“Recent reports by Herzog and others indicate that innate immune system also plays important roles in activation of immunity by AAVmediated gene transfer, both in inducing the initial response to the vector and in promoting a deleterious adaptive immune responses [24,25].”
BackgroundToll-Like Receptor 9 in Plasmacytoid Dendritic Cells Fails To Detect Parvoviruses
Mattei, L. M., Cotmore, S. F., Li, L., Tattersall, P. J., & Iwasaki, A. (2013) · Journal of Virology · doi:10.1128/jvi.03155-12 · Cited by 15
“A previous study showed that a recombinant AAV-2 vector encoding green fluorescent protein (GFP) stimulates murine Flt3L pDCs through TLR9 and MyD88 (6).”
BackgroundRedundancy in Innate Immune Pathways That Promote CD8+ T-Cell Responses in AAV1 Muscle Gene Transfer
Li, N., Kumar, S. R. P., Cao, D., Muñoz-Melero, M., Arisa, S., Brian, B. A., Greenwood, C. M., Yamada, K., Duan, D., & Herzog, R. W. (2024) · Viruses · doi:10.3390/v16101507 · Cited by 14
“This is particularly well documented for sensing the AAV genome by the endosomal DNA receptor TLR9 [19,20].”
BackgroundInfluentialMokhtari, T., Taheri, M. N., Akhlaghi, S., Aryannejad, A., Xiang, Y., Mahajan, V., Kamyar Keshavarz, F., Kiani, A., Yang, S., LoPresti, S. T., et al. (2026) · ACS Synthetic Biology · doi:10.1021/acssynbio.5c00188 · Cited by 19
He, X., Sun, Y., Lu, J., Naz, F., Ma, S., & Liu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1117760 · Cited by 16
Muñoz-Melero, M., & Biswas, M. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.227 · Cited by 14
Kistner, A., Chichester, J. A., Wang, L., Calcedo, R., Greig, J. A., Cardwell, L. N., Wright, M. C., Couthouis, J., Sethi, S., McIntosh, B. E., et al. (2023) · Gene Therapy · doi:10.1038/s41434-023-00423-z · Cited by 13
“Additionally, innate immunity plays an important role in promoting anti-capsid and anti-transgene immune responses after AAV vector administration, including type I interferons (IFNs), TLR9, TLR2, and mitochondrial antiviral-signaling protein [43 – 48].”
Rescue of lysosomal acid lipase deficiency in mice by rAAV8 liver gene transfer
Laurent, M., Harb, R., Jenny, C., Oustelandt, J., Jimenez, S., Cosette, J., Landini, F., Ferrante, A., Corre, G., Vujić, N., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00816-8 · Cited by 13
Current and Future Treatments for Lysosomal Storage Disorders
Rastall, D. P. W., & Amalfitano, A. (2017) · Current Treatment Options in Neurology · doi:10.1007/s11940-017-0481-2 · Cited by 15
Novel Lung Tropic Adeno-Associated Virus Capsids for Therapeutic Gene Delivery
Carneiro, A. D., Lee, H., Lin, L. W., van Haasteren, J., & Schaffer, D. V. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.169 · Cited by 13
“28,29 Such cytokine secretion induces inflammation and modulates adaptive immune responses, including the activation of CD4 + T cell and CD8 + T cells.”
Immune responses in retinal gene therapy: challenges, mechanisms, and future strategies
Ma, Y., & Shen, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1664968 · Cited by 15
“…motifs more ef fi ciently than single stranded genomes and consequently elicit stronger endosomal TLR9 dependent MyD88 signaling, type I interferon (IFN) responses, and capsid speci fi c CD8 + T cell priming; these effects are markedly blunted in Tlr9 de fi cient or Myd88 de fi cient mice (19 – 21).”
Lopes, J. A., Rghei, A. D., Thompson, B., Susta, L., Khursigara, C. M., & Wootton, S. K. (2022) · Biomedicines · doi:10.3390/biomedicines10123162 · Cited by 15
“TLR2 and TLR9 are activated through sensing of the AAV capsid and genomic DNA, respectively, which can decrease transgene expression and increase immunogenicity [122,123].”
BackgroundAbdel‐Motal, U. M., Harbison, C., Han, T., Pudney, J. A., Anderson, D. J., Zhu, Q. K., Westmoreland, S. V., & Marasco, W. A. (2014) · Gene Therapy · doi:10.1038/gt.2014.56 · Cited by 12
Hayashita‐Kinoh, H., Posadas-Herrera, G., Nitahara‐Kasahara, Y., Kuraoka, M., Okada, H., Chiyo, T., Takeda, S., & Okada, T. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.11.003 · Cited by 11
“12 The relevance of immune effects during gene transfer is emphasized by the results of a recent clinical gene therapy trial of rAAV2.”
Kashiwakura, Y., Endo, K., Ugajin, A., Kikuchi, T., Hishikawa, S., Nakamura, H., Katakai, Y., Baatartsogt, N., Hiramoto, T., Hayakawa, M., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.08.016 · Cited by 12
Alakhras, N. S., Moreland, C. A., Wong, L. C., Raut, P., Kamalakaran, S., Wen, Y., Siegel, R. W., & Malherbe, L. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1354055 · Cited by 10
“In murine models, TLR9 sensing of AAV in plasmacytoid dendritic cells (pDCs) and the resulting type I IFN response are critical for the induction of the cellular and humoral immune response to AAV (9, 10).”
BackgroundInfluentialJarvi, N. L., Hofman, K., Venkatesh, A., Gorecki, E., & Balu‐Iyer, S. V. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.09.006 · Cited by 10
Iroanya, G. I., Subramanyam, P. N., Wells, K. D., & Green, J. A. (2025) · Human Gene Therapy · doi:10.1177/10430342251378524 · Cited by 11
“32 Additionally, both vector-derived genomes and stress-induced mitochondrial DNA (mtDNA) can leak into the cytosol where they serve as danger-associated molecular patterns that activate cytosolic DNA sensors such as cyclic GMP-AMP synthase (cGAS).”
Zhang, P., Luo, X., Bird, A., Li, S., & Koeberl, D. D. (2012) · BioResearch open access · doi:10.1089/biores.2012.0217 · Cited by 12
“It has been shown that the innate immune responses to AAV2 vectors are primarily through the TLR9-MyD88 pathway.(18) The role of MyD88/TRIF signaling pathway in shaping the antibody responses to the AAV-CBhGAA vector was unknown, and therefore we investigated how MyD88/ TRIF signaling affects antibody responses to AAV…”
BackgroundOrtved, K. F., Austin, B. S., Scimeca, M. S., & Nixon, A. J. (2016) · Arthritis · doi:10.1155/2016/3484961 · Cited by 12
“Both AAV and shRNA duplexes are capable of activating an intracellular immune response through TLR-9 or TLR-7 signaling, respectively [31, 32].”
BackgroundKang, M. H., Thomas, S. P., Westley, C., Blouin, T., Xu, L., Chan, Y., Lisk, E., Allen, S., Vadivel, A., Nangle, K., et al. (2025) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0247oc · Cited by 9
Characteristics of BAY 2599023 in the Current Treatment Landscape of Hemophilia A Gene Therapy
Pipe, S. W., Arruda, V. R., Lange, C., Kitchen, S., Eichler, H., & Wadsworth, S. C. (2022) · Current Gene Therapy · doi:10.2174/1566523222666220914105729 · Cited by 9
“Innate immunity is critically important, including the interaction of the single-stranded DNA genome of AAV with Toll-like receptor (TLR)9MyD88, leading to the production of type I interferon [95].”
BackgroundKleven, M. D., Gomes, M. M., Wortham, A. M., Enns, C. A., & Kahl, C. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194728 · Cited by 9
Viral-mediated gene therapy in pediatric neurological disorders
Peng, J., Zou, W., Wang, X., Zhang, Z., Huo, R., & Yang, L. (2023) · World Journal of Pediatrics · doi:10.1007/s12519-022-00669-4 · Cited by 11
“Additionally, the innate immune response of human plasmacytes and dendritic cells to AAV is mediated by TLR9, which is further triggered by myeloid differentiation primary response 88 (MYD88) [72].”
Seitz, I. P., Rodríguez‐Bocanegra, E., Bucher, K., Reichel, F. F., Michalakis, S., Romanovsky, D., Biel, M., Wissinger, B., Bartz‐Schmidt, K. U., Peters, T. M., et al. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.6.38 · Cited by 9
“The use of pDCs as an AAV-sensing, immunocompetent in vitro cell model was first described by Zhu et al. 18 Previous work of our group has used the pDC model to investigate TLR9-mediated immunogenicity of various AAV preps.”
Use of CD19-targeted immune modulation to eradicate AAV-neutralizing antibodies
Doshi, B. S., Markmann, C., Novak, N. C., Rojas, S. J., Davidson, R. J., Chau, J. Q., Wang, W., Carrig, S., Rus, C. M., Samelson‐Jones, B. J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.003 · Cited by 9
“The innate immune response to AAV is facilitated by toll-like receptor 9 and MyD88 signaling 39,40 followed by activation of CD4 + and CD8 + T cells via antigen presentation on major histocompatibility complexes.”
Ferrand, M., Rocha, S. D., Corre, G., Galy, A. H. M., & Boisgérault, F. (2015) · Molecular Therapy · doi:10.1038/mt.2015.59 · Cited by 8
Smith, M. C., Belur, L. R., Karlen, A. D., Erlanson, O., Furcich, J. W., Lund, T. C., Seelig, D. M., Kitto, K. F., Fairbanks, C. A., Kim, K. H., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101201 · Cited by 9
“43,44 Our data showing a reduced threshold impact as the dose is increased from 10 9 gc to 10 11 gc (in which a smaller percentage of the overall dose is neutralized by the threshold effect) is consistent with such an antibody or cellular mechanism.”
BackgroundAdeno‐associated viral vector gene therapy: Challenges for the paediatric hepatologist
Jagadisan, B., & Dhawan, A. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12326 · Cited by 9
AAV Entry: Filling in the Blanks
Büning, H. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.015 · Cited by 9
“The GPR108-TLR9 interaction might be of interest as this TLR is a well-described pattern recognition receptor for AAV vectors, which triggers a type I interferon response following recognition of AAV vector genomes, thereby initiating adaptive immune responses against the vector and/or the transgene product.(12) Dudek…”
BackgroundDargaud, Y. G., Yamaguti-Hayakawa, G. G., Frade-Guanaes, J. O., Leuci, A., & Ozelo, M. C. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101353 · Cited by 9
Araujo, A. E., Bentler, M., Garmendia, X. P., Kaleem, A., Fabian, C., Morgan, M. A., Hacker, U. T., & Büning, H. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.114 · Cited by 7
“16 – 18 TLR, toll-like receptor. contrast, in PBMC of seronegative individuals, neither B nor T cells responded to AAV capsids, while a NK cell subtype became activated and transiently produced cytokines, including IFN-c and TNF-a .”
InfluentialMolina, E., Tejero, M., Duzenli, O. F., Kuoch, H., Caine, C., Krotova, K. Y., Paulaitis, M. E., & Aslanidi, G. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101358 · Cited by 7
Abdelhamid, L., & Mazor, R. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01127-5 · Cited by 7
“Studies suggest involvement of redundant innate sensors, such as the Toll Like Receptors (TLRs) with TLR9 as the major driver of AAV-immunogenicity, sensing unmethyl-ated CpG motifs on the DNA of the AAV (40, 41), particularly after systemic administration (42).”
Li, Z., Ding, G., Wang, Y., Zheng, Z., & Lv, J. (2020) · Translational Neuroscience · doi:10.1515/tnsci-2020-0132 · Cited by 7
Targeting Co-Stimulatory Pathways in Gene Therapy
Huang, X., & Yang, Y. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00202 · Cited by 7
“One way to interfere with the TLR9–MyD88-type I IFN signaling pathway is to use antagonists specific to TLR9 such as inhibitory ODN to block the TLR9–MyD88 pathway (Zhu et al., 2009; Martino et al., 2011).”
BackgroundInfluentialSelf-citationGlenn, J. D., Negash, H., Henry, W., Qian, R., Liu, Y., Danos, O., Bruder, J. T., & Karumuthil-Melethil, S. (2024) · Cellular Immunology · doi:10.1016/j.cellimm.2024.104823 · Cited by 6
Miller, Z. M., Lin, L. F., Schaffer, D. V., & Williams, E. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101608 · Cited by 6
Moradian, H., Dunne, C. M., Gossen, M., & Hartlieb, M. (2025) · Advanced Science · doi:10.1002/advs.202512653 · Cited by 7
Luo, S., Jiang, H., Li, Q., Yang, S., Yu, X., Xu, X., Xie, Q., Ke, X., & Zheng, Q. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121518 · Cited by 6
“…of TLR-9 in rAAV not only results in the acute expression of cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α ) downstream of TLR signaling but also promotes the infiltration of cytotoxic CD8+ T cells, ultimately leading to the loss of transduced target cells [50,51].”
Touramanidou, L., Gurung, S., Cozmescu, A. C., Perocheau, D. P. B., MOULDING, D. A., Deborah, R., Cavedon, A., Siddiqui, S., Rice, L., Finn, P. F., et al. (2024) · Cells · doi:10.3390/cells13231979 · Cited by 8
Gene Therapy: Contest between Adeno-Associated Virus and Host Cells and the Impact of UFMylation
Maurya, S., & Jayandharan, G. R. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00512 · Cited by 6
Muramatsu, S., Hwu, W., & Gidoni-Ben-Zeev, B. (2021) · Current Gene Therapy · doi:10.2174/1566523221666210922155413 · Cited by 6
Cai, X., Zhang, X., & Bai, H. (2020) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/ypgx4 · Cited by 6
Grubor, B., Henry, K. L., Chan, S. J., Sheehan, M. J., Shah, A., Pellerin, A., Bai, J., Nadella, P., Bommegowda, S., Cullen, P. F., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101643 · Cited by 6
“While four spinal cord modules (SC12, 14, 15, and 16) demonstrated significant changes in response to AAV, none of these changes preceded histopathology findings (i.e., were present only on day 15 and/or 29) (Table S4).”
Liu, Z., & Song, S. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102911 · Cited by 7
Tomczyk, M., Kraszewska, I., Mąka, R., Waligórska, A., Dulak, J., & Jaźwa, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240691 · Cited by 5
“This is in agreement with other data indicating that AAVs in the liver activate rather plasmacytoid dendritic cells (pDCs) than non-pDCs such as KCs, to produce type I interferons through the TLR9-MyD88 pathway [18].”
ResultAAV Vector-Based Gene Therapy, Progress and Current Challenges
Kuranda, K., & Mingozzi, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_5 · Cited by 5
Masri, S., Carré, L., Jaulin, N., Vandamme, C., Couzinié, C., Guy‐Duché, A., Dupont, J.-B., Pereira, A., Charpentier, É., David, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310447 · Cited by 6
“In contrast, several studies using rAAV1, 2 and 9 reported an activation of dendritic cells by AAV vectors through the TLR9/MyD88 pathway using in vitro and in vivo mouse models [20,21].”
BackgroundResultInfluentialRajapaksha, I. G., Angus, P., & Herath, C. B. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.80317 · Cited by 7
“immune responses against the AAV proteins, including the route of administration, dose, serotype, host species, transgene and expression cassettes, and pre-existing immunity to AAV [6, 58].”
BackgroundSafety of in vivo gene therapy in children: mechanisms and management of liver injury
Jeyaraj, R., Brown, L. K., Jagadisan, B., Muntoni, F., Baruteau, J., Gupte, G. L., Breuer, J., Gissen, P., Oo, Y. H., & Dhawan, A. (2026) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(25)00380-3 · Cited by 5
Liver health in hemophilia in the era of gene therapy
Dargaud, Y. G., Levrero, M., Bailly, F., Lienhart, A., & Zoulim, F. (2024) · Thrombosis Research · doi:10.1016/j.thromres.2024.109064 · Cited by 4
Rapti, K., Hajjar, R. J., & Weber, T. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-891-7_12 · Cited by 4
Wang, Q., Zhang, L., Zhang, G., Mao, J.-H., Xi, X., Jiang, L., Lv, G., Lu, J., Shen, Y., Chen, Z., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110887118 · Cited by 4
Self-citationChallenges to Gene Editing Approaches in the Retina
Bonillo, M., Pfromm, J. K., & Fischer, M. D. (2022) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1757-9810 · Cited by 6
“AAV transduction of murine and human plasmacytoid dendritic cells lead to an induction of transient cytoand chemokine responses via the activation of the TLR-9 pathway [81].”
BackgroundViral vectors in neurodegenerative diseases: immune responses and therapeutic applications
Wang, Y., Mu, S., & Liu, F. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1603125 · Cited by 7
“…response gene 88 (MyD88) for downstream signaling, leading to type I IFNs production in pDCs and further promoting activation of CD8 + T cells (93, 96). pDCs recognize AAV genomes via TLR9 and release type I interferons, which in turn activate conventional dendritic cells to prime…”
Tissue‐specific gene delivery approaches
Nasr, S. S., Cheema, Y., Stern, A., Tabah, O., Poore, S., & Duncan, G. A. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70125 · Cited by 4
“139 In addition, they showed that PACE polymers with a MW mRNA, in which the polymeric material initially conveys a positive charge in order to complex with the negatively charged mRNA.”
Transgene Expression in Cultured Cells Using Unpurified Recombinant Adeno-Associated Viral Vectors
Benyamini, B., Esbin, M. N., Whitney, O. N., Walther, N., & Maurer, A. C. (2023) · Journal of Visualized Experiments · doi:10.3791/65572 · Cited by 2
Clinical and Ocular Inflammatory Inhibitors of Viral-Based Gene Therapy of the Retina
Ohlhausen, M. E., & Conrady, C. D. (2024) · Acta Microbiologica Hellenica · doi:10.3390/amh69030018 · Cited by 2
Use of Mesenchymal Stem Cells to Enhance the Efficacy of Gene Therapy
Hayashita‐Kinoh, H., & Okada, T. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2772-3_19 · Cited by 1
Liver dysfunction in AAV-mediated Hemophilia B gene therapy: Mechanisms and management strategies
Song, X., Ding, B., Jia, H., & Zhou, H. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101356 · Cited by 2
Ren, D., Chauveau, G. A., Cabon, E., Vendomèle, J., Vignal‐Clermont, C., Saliba, H., Ail, D., Dalkara, D., & Fisson, S. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101443 · Cited by 1
Ou, Y., Wu, F., He, C., Luo, S., Guo, Z., Zhang, Y., Hu, R., Xu, Y., Tang, X., Zhao, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71194-5 · Cited by 1
Gene delivery for cerebral neurodegenerative disorders: Current advancements and limitations
Dayma, K., & Upadhyay, A. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.06.030 · Cited by 2
Immune System Obstacles to In vivo Gene Transfer with Adeno-Associated Virus Vectors
Büning, H., & Mingozzi, F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00004-x · Cited by 1
Worgall, S., & Crystal, R. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818422-6.00029-0 · Cited by 3
Detection of Humoral Response to Transgene Protein and Gene Editing Reagents
Buchlis, G., & Gorovits, B. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch12 · Cited by 1
Gaston, C., Fayard, A., Dufour, N., Hantraye, P., Badin, R. A., & Bemelmans, A. (2025) · Revue de primatologie · doi:10.4000/15jub · Cited by 1
Bello, A. J. A. (2014) · Mspace (University of Manitoba) · Cited by 1
Improving lentiviral vector-mediated gene transfer by understanding cellular barriers
Oakland, M., McCray, P. B., Maury, W. J., Davidson, B. L., Klingelhutz, A. J., & Perlman, S. M. (2013) · doi:10.17077/etd.f63i1jvz
Komegae, E. N. (2010) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2010.tde-01102010-120643 · Cited by 1
“Diversos autores afirmam que a estimulação destes receptores inatos é decisiva para a geração de respostas T dependentes de memória de grande magnitude, qualidade e de longa duração (ZHU et al., 2007; QUIGLEY et al., 2009; ZHU et al., 2009).”
BackgroundTranslational Challenges for Hepatocyte-Directed Gene Transfer
Stephanie, C., Van, E., Jacobs, F., & De, B. (2011) · InTech eBooks · doi:10.5772/22930
Progress and challenges in gene therapy for Crigler–Najjar syndrome
Aronson, S. J., Beuers, U. H., & Bosma, P. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1100991 · Cited by 1
Principles and Practice of Molecular Therapies
Rodino‐Klapac, L. R., & Mendell, J. R. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-417044-5.00051-2
Ghenassia, A. (2015) · theses.fr (ABES) · doi:10.70675/258b493cz74a9z4788zbbb4za8046cd94fe0 · Cited by 2
Intracellular fate of AAV particles in human Dendritic Cell and impact on Gene Transfer
Rossi, A. (2016) · theses.fr (ABES) · doi:10.70675/4518d4eazdbd8z4f46z96e2zf87942913c70
“Moreover, the vector genome may be also detected by the innate immune system, via TLR-9, similarly resulting in the activation of MyD88 pathway [69].”
BackgroundIslam, K. U., & Iqbal, J. (2019) · Springer eBooks · doi:10.1007/978-981-32-9449-3_12
Mingozzi, F., & Junge, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-63671-1.00033-1
Benefits and Shortcomings of Laboratory Model Systems in the Development of Genetic Therapies
Bucher, K., Rodríguez‐Bocanegra, E., & Fischer, M. D. (2022) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1757-9879
“first described the involvement of the TLR9 pathway in the recognition of viral DNA from AAV8 and AAV2 using mouse pDCs [35].”
BackgroundMethodMyD88 (Myeloid Differentiation Primary Response Gene 88)
Basith, S., Manavalan, B., & Choi, S. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_588-1
MyD88 (Myeloid Differentiation Primary Response Gene 88)
Basith, S., Manavalan, B., & Choi, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_588
MyD88, Myeloid Differentiation Primary Response Gene 88
Basith, S., Manavalan, B., & Choi, S. (2012) · Springer eBooks · doi:10.1007/978-1-4419-0461-4_588
Strecker, M. (2022) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.68021
Kaugars, K. E., Retamal-Díaz, A. R., de Oliveira, A. P., González, P. A., & Jacobs, W. R. (2022) · Journal of Cellular Immunology · doi:10.33696/immunology.4.149
“Even in adenoviral vectors, MyD88 and TLR9 are critical in eliciting a strong antibody response [73].”
BackgroundAssaf, B. T., Harper, C. G., & Phillips, J. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00034-8 · Cited by 2
Benyamini, B., Esbin, M. N., Whitney, O. N., Walther, N., & Maurer, A. C. (2023) · doi:10.3791/65572-v
Intrathecal Delivery of Viral Vector-Mediated Gene Therapy
Keifer, O. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-39558-1_16
Metadata
- Authors
- Zhu, J., Huang, X., & Yang, Y.
- Affiliations
- Duke Medical Center (US)
- Duke University (US)
- Corresponding author
- Yang, Yiping
- Venue
- Journal of Clinical Investigation
- Published
- 2009-08-03
- Volume
- 119
- Issue
- 8
- Pages
- 2388-2398
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2719948
- OpenAlex
- W2043149070
- Semantic Scholar
- 9808ef8c0218096852d97ab403f3e3a9feeb2215
- Cited by
- 330
- References
- 73
- Citations by year
- 2026: 23 · 2025: 20 · 2024: 26 · 2023: 31 · 2022: 29 · 2021: 27 · 2020: 29 · 2019: 24 · 2018: 16 · 2017: 17 · 2016: 7 · 2015: 15 · 2014: 10 · 2013: 15 · 2012: 11
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (CA047741)
- University of North Carolina at Chapel Hill
- National Cancer Institute (CA111807, CA047741, P01CA047741, R01CA111807)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, AAV gene therapy, TLR9, MyD88, type I interferon, plasmacytoid dendritic cells, innate immunity, adaptive immune response, CD8+ T cells, AAV capsid, neutralizing antibodies, transgene expression, immunogenicity
- MeSH terms
- Dependovirus, Animals, Cells, Cultured, Dendritic Cells, Genetic Vectors, Humans, Immunity, Innate, Interferon Type I, Mice, Inbred BALB C, Mice, Inbred C57BL, Genetic Therapy, Signal Transduction, CD8-Positive T-Lymphocytes, Transgenes, Toll-Like Receptor 9, Mice, Myeloid Differentiation Factor 88
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.